T. Younis

427 total citations
32 papers, 308 citations indexed

About

T. Younis is a scholar working on Oncology, Economics and Econometrics and Cancer Research. According to data from OpenAlex, T. Younis has authored 32 papers receiving a total of 308 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 10 papers in Economics and Econometrics and 10 papers in Cancer Research. Recurrent topics in T. Younis's work include Breast Cancer Treatment Studies (10 papers), Economic and Financial Impacts of Cancer (10 papers) and Estrogen and related hormone effects (7 papers). T. Younis is often cited by papers focused on Breast Cancer Treatment Studies (10 papers), Economic and Financial Impacts of Cancer (10 papers) and Estrogen and related hormone effects (7 papers). T. Younis collaborates with scholars based in Canada, United Kingdom and Switzerland. T. Younis's co-authors include Daniel Rayson, Chris Skedgel, Ron Dewar, Nathalie Saint‐Jacques, Kiran Virik, M. Dorreen, Snežana Jovanović, Ravi Ramjeesingh, Swarna Weerasinghe and Theresa Hahn and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and British Journal of Cancer.

In The Last Decade

T. Younis

29 papers receiving 306 citations

Peers

Countries citing papers authored by T. Younis

Since Specialization

Citations

This map shows the geographic impact of T. Younis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by T. Younis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites T. Younis more than expected).

Fields of papers citing papers by T. Younis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by T. Younis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by T. Younis. The network helps show where T. Younis may publish in the future.

Co-authorship network of co-authors of T. Younis

This figure shows the co-authorship network connecting the top 25 collaborators of T. Younis. A scholar is included among the top collaborators of T. Younis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with T. Younis. T. Younis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Women’s Views about Breast Cancer Prevention at Mammography Screening Units and Well Women’s Clinics 2020 ·Current Oncology ·Andrew Rundle, Sian Iles, (unknown), Leah E. Cahill, Cynthia C. Forbes, Nathalie Saint‐Jacques, Robin Urquhart, T. Younis	4
2	Economic Evaluation of Adjuvant Trastuzumab Emtansine in Patients with HER2-Positive Early Breast Cancer and Residual Invasive Disease after Neoadjuvant Taxane and Trastuzumab–Based Treatment in Canada 2020 ·Current Oncology ·T. Younis, (unknown), Megan Coombes, Nathaniel Bouganim, Daniel Becker, Cédric Révil, (unknown)	8
3	Palliative Care Consultation and Aggressive Care at End of Life in Unresectable Pancreatic Cancer 2019 ·Current Oncology ·(unknown), Swarna Weerasinghe, (unknown), T. Younis, Ravi Ramjeesingh	13
4	Cost-effectiveness of febrile neutropenia prevention with primary versus secondary G-CSF prophylaxis for adjuvant chemotherapy in breast cancer: a systematic review 2016 ·Breast Cancer Research and Treatment ·T. Younis, Daniel Rayson, Snežana Jovanović, Chris Skedgel	14
5	Cost–Utility of Adjuvant Zoledronic Acid in Patients with Breast Cancer and Low Estrogen Levels 2015 ·Current Oncology ·(unknown), Chris Skedgel, Daniel Rayson, T. Younis	0
6	The Value-for-Money of Adjuvant Aromatase Inhibitors: Time to Put the Debate to Rest? 2015 ·Current Oncology ·T. Younis, (unknown)	2
7	Is adjuvant trastuzumab a cost-effective therapy for HER-2/neu-positive T1bN0 breast cancer? 2013 ·Annals of Oncology ·Chris Skedgel, Daniel Rayson, T. Younis	10
8	Drug-Induced Subacute Cutaneous Lupus Erythematosus Associated with Nab-Paclitaxel Therapy 2013 ·Current Oncology ·(unknown), T. Younis, (unknown), M. Dorreen	20
9	Incidence of Febrile Neutropenia during Adjuvant Chemotherapy for Breast Cancer: A Prospective Study 2012 ·Current Oncology ·Daniel Rayson, (unknown), (unknown), Brian Colwell, M. Dorreen, (unknown), (unknown), Stephanie Snow, T. Younis	8
10	Chemotherapy Uptake and Wait Times in Early-Stage Non-Small-Cell Lung Cancer 2012 ·Current Oncology ·(unknown), (unknown), Nathalie Saint‐Jacques, Daniel Rayson, T. Younis	4
11	Adjuvant endocrine monotherapy with tamoxifen or aromatase inhibitors for postmenopausal women with breast cancer: What is the economic impact of CYP 2D6 testing? 2010 ·Journal of Clinical Oncology ·T. Younis, Daniel Rayson, Chris Skedgel	0
12	The Cost Burden of Trastuzumab and Bevacizumab Therapy for Solid Tumours in Canada 2008 ·Current Oncology ·(unknown), Chris Skedgel, Kiran Virik, Daniel Rayson, (unknown), T. Younis	35
13	Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma 2007 ·Bone Marrow Transplantation ·Mustafa Beneklı, (unknown), T. Younis, M. S. Czuczman, Francisco J. Hernandez‐Ilizaliturri, (unknown), Minoo Battiwalla, (unknown), Philip L. McCarthy, Theresa Hahn	19
14	Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: Upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole 2007 ·The Breast ·Chris Skedgel, Daniel Rayson, Ron Dewar, T. Younis	19
15	Wait times for breast cancer care 2006 ·British Journal of Cancer ·Nathalie Saint‐Jacques, T. Younis, Ron Dewar, Daniel Rayson	31
16	Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole 2006 ·Breast Cancer Research and Treatment ·Chris Skedgel, Daniel Rayson, Ron Dewar, T. Younis	25
17	Modeling for cost-effective-adjuvant aromatase inhibitor strategies for postmenopausal women with breast cancer 2006 ·Annals of Oncology ·T. Younis, Daniel Rayson, Ron Dewar, Chris Skedgel	13
18	Economic evaluation of adjuvant chemotherapy in Stage III (SIII) colon cancer: Capecitabine versus 5FU/LV 2006 ·Journal of Clinical Oncology ·Kiran Virik, Chris Skedgel, T. Younis	3
19	Patterns of trastuzumab use and cost in a single Canadian cancer institute 2005 ·Journal of Clinical Oncology ·Kylea Potvin, T. Younis, (unknown), Penny J. Barnes, Daniel Rayson	7
20	Economic evaluation of adjuvant hormonal options in postmenopausal women with breast cancer: Tamoxifen vs tamoxifen then exemestane vs anastrazole 2005 ·Journal of Clinical Oncology ·Chris Skedgel, Daniel Rayson, Ron Dewar, Kylea Potvin, T. Younis	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact